Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
Zhiheng Xu,Yongbo Huang,Jianmeng Zhou,Xiumei Deng,Weiqun He,Xiaoqing Liu,Yimin Li,Nanshan Zhong,Ling Sang +8 more
Reads0
Chats0
TLDR
In this article, the potential value of mesenchymal stromal cells (MSCs) as a therapeutic strategy for the coronavirus disease 2019 (COVID-19) pandemic was evaluated.Abstract:
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted the urgent need for novel therapies. Cell-based therapies, primarily using mesenchymal stromal cells (MSCs), have demonstrated safety and potential efficacy in the treatment of critical illness, particularly sepsis and acute respiratory distress syndrome (ARDS). However, there are limited preclinical data for MSCs in COVID-19. Recent studies have shown that MSCs could decrease inflammation, improve lung permeability, enhance microbe and alveolar fluid clearance, and promote lung epithelial and endothelial repair. In addition, MSC-based therapy has shown promising effects in preclinical studies and phase 1 clinical trials in sepsis and ARDS. Here, we review recent advances related to MSC-based therapy in the context of sepsis and ARDS and evaluate the potential value of MSCs as a therapeutic strategy for COVID-19.read more
Citations
More filters
Journal ArticleDOI
Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial
Antoine Monsel,Caroline Hauw-Berlemont,Miryam Mebarki,N Heming,Julien Mayaux,Otriv Nguekap Tchoumba,Jean-Luc Diehl,Alexandre Demoule,Djillali Annane,Clémence Marois,Sophie Demeret,Emmanuel Weiss,Guillaume Voiriot,Muriel Fartoukh,Jean-Michel Constantin,Bruno Mégarbane,Gaëtan Plantefève,Stéphanie Malard-Castagnet,Sonia Burrel,Michelle Rosenzwajg,Nicolas Tchitchek,Hélène Boucher-Pillet,Guillaume Churlaud,Audrey Cras,Camille Maheux,Chloé Pezzana,Mamadou Hassimiou Diallo,Jacques Ropers,Philippe Menasché,Jérôme Larghero,Deborah Benchetrit,Harold Bonvallot,Fanny Charbonnier-Beaupel,Meriem Dhib-Charfi,P. Delmotte,A. Koné,Marine Le Corre,Anne-Geneviève Marcelin,Carole Metz,Louis Puybasset,Joe-Elie Salem,Corinne Vezinet +41 more
TL;DR: In this article , a randomized, double-blind, randomized, placebo-controlled trial (STROMA-CoV-2) was conducted to assess the efficacy of Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in patients with acute respiratory syndrome coronavirus-2-induced acute respiratory distress syndrome (ARDS) causing high mortality.
Journal ArticleDOI
Electroacupuncture Alleviates LPS-Induced ARDS Through α7 Nicotinic Acetylcholine Receptor-Mediated Inhibition of Ferroptosis
Yiguo Zhang,Li Zheng,Huimin Deng,Di Feng,Song Hu,Lina Zhu,Wenting Xu,Wenyu Zhou,Yu Wang,Keting Min,Qing Zhou,Yuanli Chen,Huanping Zhou,Hao Yang,Xin Lv +14 more
TL;DR: Electroacupuncture stimulation could alleviate LPS-induced ARDS by activating α7nAchR to inhibit L PS-induced ferroptosis in alveolar epithelial cells, and it was demonstrated that the pulmonary protective effects of EA stimulation were effectively reversed by erastin, a ferroPTosis activator.
Journal ArticleDOI
Translating MSC Therapy in the Age of Obesity
TL;DR: Current evidence that obesity alters MSC immunomodulatory function, drastically modifies the host immune system, and therefore reshapes interactions between MSCs and immune cells is outlined.
Journal ArticleDOI
Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis
TL;DR: Wang et al. as mentioned in this paper investigated the efficacy and safety of mesenchymal stromal cells (MSCs) in treating severe/critical patients with COVID-19, with placebo or standard treatment as the control group.
Journal ArticleDOI
COVID-19 inflammation and implications in drug delivery
TL;DR: In this article , the implication of COVID-19 inflammation can be exploited as a therapeutic target and/or a targeting strategy against the pandemic, and the drug delivery systems can be harnessed to improve the properties of anti-inflammatory agents and deliver them safely and efficiently to their therapeutic targets.
References
More filters
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Massimo Dominici,K. Le Blanc,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Diane S. Krause,Robert J. Deans,Armand Keating,Darwin J. Prockop,Edwin M. Horwitz +9 more
TL;DR: The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
Journal ArticleDOI
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer,Clifford S. Deutschman,Christopher W. Seymour,Manu Shankar-Hari,Djillali Annane,Michael Bauer,Rinaldo Bellomo,Gordon R. Bernard,Jean-Daniel Chiche,Craig M. Coopersmith,Richard S. Hotchkiss,Mitchell M. Levy,John C. Marshall,Greg S. Martin,Steven M. Opal,Gordon D. Rubenfeld,Gordon D. Rubenfeld,Tom van der Poll,Jean Louis Vincent,Derek C. Angus +19 more
TL;DR: The task force concluded the term severe sepsis was redundant and updated definitions and clinical criteria should replace previous definitions, offer greater consistency for epidemiologic studies and clinical trials, and facilitate earlier recognition and more timely management of patients with sepsi or at risk of developing sepsic shock.
Journal ArticleDOI
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
TL;DR: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d
Journal ArticleDOI
Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
Roger C. Bone,Robert A. Balk,F. B. Cerra,R. P. Dellinger,A. M. Fein,William A. Knaus,Roland M. H. Schein,W. J. Sibbald +7 more
TL;DR: An American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference was held in Northbrook in August 1991 with the goal of agreeing on a set of definitions that could be applied to patients with sepsis and its sequelae as mentioned in this paper.